drugset
drugset / Trial / NCT02171806

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

NCT02171806 ↗

Phase 1 Completed 47 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1744 CL

Timeline

Start
2006-01
Primary completion
2006-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 2.5 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled
Subject Olodaterol Small molecule 30 ug Inhaled

Indications

No indication recorded.